# CrossPoint Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/crosspoint-therapeutics

- Industry: Biotechnology
- Headquarters: Hwaseong, South Korea
- Website: www.crosspointrx.com/
- Total disclosed funding: $1.6M
- Latest round: Seed (Apr 1, 2024)
- Investors on record: 4

## About

Based in Hwaseong, South Korea, and founded in 2022 by CEO Tae-Erk Kim, CrossPoint Therapeutics operates as a provider of dual-target immuno-oncology drugs and antibody-drug conjugate therapies that use its stealth-body platform technology to treat refractory diseases. In March 2026, CrossPoint Therapeutics raised KRW 3.6 billion in pre-series A funding co-led by Kudos Ventures and Soo Investment Capital, with participation from Y-Biologics and BMI Korea.

The company provides a wide range of biotechnological solutions, such as protein delivery CPP-001, small molecule delivery CPS-001, and gene delivery CPR-001, with the help of Stealth-Body technology. Additionally, the firm offers research and development services in smart cell targeting.

The company will use the March 2026 funding to obtain preliminary toxicity data from monkey studies within the year.

## Funding rounds

- Seed, Apr 1, 2024, $1.6M — Kite Entrepreneurship Foundation, Korea Omega Investment Corp., Infobank, Korea University Holdings

## Investors

- Kite Entrepreneurship Foundation — Seed
- Korea Omega Investment Corp. (https://capitalatlas.ai/funds/korea-omega-investment-corp) — Seed
- Infobank (https://capitalatlas.ai/funds/infobank) — Seed
- Korea University Holdings (https://capitalatlas.ai/funds/korea-university-holdings) — Seed